N-[5-(1-methylimidazol-2-yl)-4-phenyl-1,3-thiazol-2-yl]-3-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)propanamide
C23H19N7O2S — CID 55515234
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[5-(1-methylimidazol-2-yl)-4-phenyl-1,3-thiazol-2-yl]-3-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)propanamide
N-[5-(1-methylimidazol-2-yl)-4-phenyl-1,3-thiazol-2-yl]-3-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)propanamide (PubChem CID 55515234) has the molecular formula C23H19N7O2S and a molecular weight of 457.52 g/mol. Its IUPAC name is N-[5-(1-methylimidazol-2-yl)-4-phenyl-1,3-thiazol-2-yl]-3-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)propanamide.
Molecular Properties
| Compound Name | N-[5-(1-methylimidazol-2-yl)-4-phenyl-1,3-thiazol-2-yl]-3-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)propanamide |
|---|---|
| PubChem CID | 55515234 |
| Molecular Formula | C23H19N7O2S |
| Molecular Weight | 457.52 g/mol |
| Exact Mass | 457.13 |
| IUPAC Name | N-[5-(1-methylimidazol-2-yl)-4-phenyl-1,3-thiazol-2-yl]-3-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)propanamide |
| SMILES | Cn1ccnc1-c1sc(NC(=O)CCc2nc(-c3ccncc3)no2)nc1-c1ccccc1 |
| InChI | InChI=1S/C23H19N7O2S/c1-30-14-13-25-22(30)20-19(15-5-3-2-4-6-15)28-23(33-20)26-17(31)7-8-18-27-21(29-32-18)16-9-11-24-12-10-16/h2-6,9-14H,7-8H2,1H3,(H,26,28,31) |
| InChIKey | KPWSDPZHQVINHK-UHFFFAOYSA-N |
| XLogP | 4.23 |
| TPSA | 111.62 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 457.52 |
| LogP ≤ 5 | 4.23 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 55515234 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.